Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Via Christi Cancer Center at Via Christi Regional Medical Center
mi
from
Wichita, KA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Via Christi Cancer Center at Via Christi Regional Medical Center
mi
from
Wichita, KA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Morton Hospital & Medical Center
mi
from
Taunton, MA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Morton Hospital & Medical Center
mi
from
Taunton, MA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Saint Joseph Mercy Cancer Center
mi
from
Ann Arbor, MI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Saint Joseph Mercy Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Genesys Hurley Cancer Institute
mi
from
Flint, MI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Genesys Hurley Cancer Institute
mi
from
Flint, MI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Hurley Medical Center
mi
from
Flint, MI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Foote Hospital
mi
from
Jackson, MI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Foote Hospital
mi
from
Jackson, MI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Borgess Medical Center
mi
from
Kalamazoo, MI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Fairview Ridges Hospital
mi
from
Burnsville, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Fairview Ridges Hospital
mi
from
Burnsville, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Mercy and Unity Cancer Center at Mercy Hospital
mi
from
Coon Rapids, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Mercy and Unity Cancer Center at Mercy Hospital
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Fairview Southdale Hospital
mi
from
Edina, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Fairview Southdale Hospital
mi
from
Edina, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Mercy and Unity Cancer Center at Unity Hospital
mi
from
Fridley, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Mercy and Unity Cancer Center at Unity Hospital
mi
from
Fridley, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
mi
from
Minneapolis, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
mi
from
Robbinsdale, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Park Nicollet Cancer Center
mi
from
St. Louis Park, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Park Nicollet Cancer Center
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
United Hospital
mi
from
St. Paul, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
United Hospital
mi
from
St. Paul, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Ridgeview Medical Center
mi
from
Waconia, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Ridgeview Medical Center
mi
from
Waconia, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
CCOP - Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
CCOP - Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Veterans Affairs Medical Center - East Orange
mi
from
East Orange, NJ
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Veterans Affairs Medical Center - East Orange
mi
from
East Orange, NJ
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Somerset Medical Center
mi
from
Somerville, NJ
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Somerset Medical Center
mi
from
Somerville, NJ
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Our Lady of Mercy Medical Center Comprehensive Cancer Center
mi
from
Bronx, NY
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Our Lady of Mercy Medical Center Comprehensive Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Aultman Cancer Center at Aultman Hospital
mi
from
Canton, OH
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Aultman Cancer Center at Aultman Hospital
mi
from
Canton, OH
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Christ Hospital Cancer Center
mi
from
Cincinnati, OH
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Christ Hospital Cancer Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
MetroHealth Cancer Care Center at MetroHealth Medical Center
mi
from
Cleveland, OH
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
MetroHealth Cancer Care Center at MetroHealth Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
St. Rita's Medical Center
mi
from
Lima, OH
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
St. Rita's Medical Center
mi
from
Lima, OH
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
St. Luke's Cancer Network at St. Luke's Hospital
mi
from
Bethlehem, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
St. Luke's Cancer Network at St. Luke's Hospital
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Geisinger Medical Center
mi
from
Danville, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Easton Regional Cancer Center at Easton Hospital
mi
from
Easton, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Easton Regional Cancer Center at Easton Hospital
mi
from
Easton, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Central Pennsylvania Hematology and Medical Oncology Associates
mi
from
Lemoyne, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Central Pennsylvania Hematology and Medical Oncology Associates
mi
from
Lemoyne, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Lewistown Hospital
mi
from
Lewistown, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Lewistown Hospital
mi
from
Lewistown, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Cancer Center of Paoli Memorial Hospital
mi
from
Paoli, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Cancer Center of Paoli Memorial Hospital
mi
from
Paoli, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Joan Karnell Cancer Center at Pennsylvania Hospital
mi
from
Philadelphia, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Joan Karnell Cancer Center at Pennsylvania Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Mount Nittany Medical Center
mi
from
State College, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Mount Nittany Medical Center
mi
from
State College, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
CCOP - MainLine Health
mi
from
Wynnewood, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
CCOP - MainLine Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Lankenau Cancer Center at Lankenau Hospital
mi
from
Wynnewood, PA
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Lankenau Cancer Center at Lankenau Hospital
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials